Pre-made Enokizumab benchmark antibody ( Whole mAb, anti-IL9 therapeutic antibody, Anti-HP40/IL-9/P40 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Enokizumab biosimilar, Whole mAb, Anti-IL9 Antibody: Anti-HP40/IL-9/P40 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Enokizumab, also known as MEDI-528, is a humanized IgG1¦Ê type monoclonal antibody direct against the cytokine interleukin-9 (IL-9). This drug was developed by MedImmune and has been investigated in the treatment for asthma.
| Products Name (INN Index) | Pre-Made Enokizumab biosimilar, Whole mAb, Anti-IL9 Antibody: Anti-HP40/IL-9/P40 therapeutic antibody |
|---|---|
| INN Name | Enokizumab |
| Target | IL9 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Genaera Corporation,Ludwig Institute for Cancer Research,MedImmune |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Asthma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL9 |
| Package |
